Arcus Biosciences, Inc. (RCUS) Return on equity 2018–2025
Arcus Biosciences, Inc. (RCUS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-55.9%FY2025 · since FY2018: -21.1% → -55.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -55.9% | +2.4 pp |
| FY2024 | -58.4% | +8.1 pp |
| FY2023 | -66.5% | -25.8 pp |
| FY2022 | -40.6% | -46.9 pp |
| FY2021 | 6.3% | +30.8 pp |
| FY2020 | -24.5% | +27.2 pp |
| FY2019 | -51.7% | -30.5 pp |
| FY2018 | -21.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice